Elritercept is an investigational fusion protein designed to treat anemia by binding to and blocking select TGF-β superfamily proteins like activins and growth differentiation factors.
A modified activin receptor type IIA ligand trap fused to a human IgG1 Fc domain.
Mechanism: It inhibits signals from Activin A/B and GDF-8/11 to help rebalance blood cell production (hematopoiesis).
Effects: Preclinical and early clinical trials show it increases red blood cells, hemoglobin, reticulocytes, and platelets.
Being studied for anemia related to lower-risk myelodysplastic syndromes (MDS) and myelofibrosis
Views: 0